![](/img/cover-not-exists.png)
H04*Update of REVEL: A randomized, double-blind, phase III study of docetaxel (DOC) and ramucirumab (RAM; IMC-1121B) versus DOC and placebo (PL) in the second-line (2L) treatment of stage IV non-small cell lung cancer (NSCLC) including subgroup analysis of histology
Bidoli, P., Cappuzzo, F., Favaretto, A., Alabiso, O., Tiseo, M., Chella, A., Gebbia, V., Pizzuti, L., Paz-Ares, L., Perol, M., Garon, E., Lee, P., Zimmermann, A., Cuyun Carter, G., Migliorino, M.R.Volume:
26
Language:
english
Journal:
Annals of Oncology
DOI:
10.1093/annonc/mdv343.04
Date:
October, 2015
File:
PDF, 35 KB
english, 2015